论文部分内容阅读
选2型糖尿病患者68例,随机分为两组。治疗组,重组甘精胰岛素(长秀霖)(n=34);对照组,(甘舒霖30R胰岛素)(n=34)。分别采用每晚9点注射甘精胰岛素加阿卡波糖(三餐中嚼服)和甘舒霖30R早、晚餐前皮下注射。根据血糖水平调整胰岛素剂量,观察3个月治疗后,两组空腹血糖(FBG)、餐后2小时血糖(2hPBG)和糖化血红蛋白(HbA1c)无明显差异(P>0.05)。但甘精组低血糖发生率明显少于预混组(P<0.05),且体重无明显变化(P>0.05)。结论:甘精胰岛素联合阿卡波糖治疗2型糖尿病比较甘舒霖30R治疗T2DM均可有效降低血糖,对体重增加影响小,低血糖发生率低。
68 patients with type 2 diabetes were randomly divided into two groups. Treatment group, recombinant glargine (Changxiu Lin) (n = 34); control group, (Gan Shu-lin 30R insulin) (n = 34). Respectively, at 9 o’clock injection of insulin glargine plus acarbose (three meals chewing) and Gansu Lin 30R early, subcutaneous injection before dinner. The dose of insulin was adjusted according to the level of blood glucose. After three months of treatment, there was no significant difference in fasting blood glucose (FBG), 2hPBG and HbA1c between the two groups (P> 0.05). However, the incidence of hypoglycaemia in Gan Gan group was significantly less than that in the premixed group (P <0.05), and there was no significant change in body weight (P> 0.05). CONCLUSION: Glargine and acarbose treatment of type 2 diabetes mellitus compared with Gan Shu Lin 30R treatment of T2DM can effectively reduce blood glucose, little effect on weight gain, low incidence of hypoglycemia.